Cure My Disease

Don't miss your cure!

 Log in / Sign up

A 2.2 mm scope could spot cancerous tissue in minutes, not days

NCT ID NCT07826611

Diagnosis Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Doctors usually send colorectal tissue to a lab and wait days for results. This pilot study tests a miniaturized device called MULTISCOPE that uses light-based imaging to tell healthy tissue from cancerous tissue in real time. Researchers will examine 30 tissue samples removed during standard endoscopic surgery and compare the device's readings against conventional lab analysis. The study also checks whether the device's built-in cold plasma tool can destroy tumor cells.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MULTISCOPE, a miniaturized optical biopsy device that uses two-photon imaging and cold argon plasma
What this could lead to
If it works, doctors could one day get an instant read on whether colorectal tissue is cancerous during a procedure, without waiting days for lab results.
What could go wrong
This is a small, early-stage lab study on 30 tissue samples, not on living patients. The device may not match standard lab testing, and results from a controlled lab setting may not hold up in real clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Colonic or rectal neoplastic lesions resectable by endoscopic submucosal dissection (ESD) * Age ≥ 18 years, male and female * patients with American Society of Anesthesiologists (ASA) grades 1-3 * Signed informed consent Exclusion Criteria: * Severe medical comorbidities precluding endoscopy; * Uncontrolled coagulopathy; * Pregnancy or planned pregnancy during the period of study participation; * Life expectancy ≤2 years, as judged by the site investigator; * Refusal to sign the informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.